Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma

Abstract

High-dose therapy plus autologous stem cell transplantation (ASCT) is considered the standard of care for the front-line treatment of younger patients with multiple myeloma.[1][1] Response rates to induction therapy prior to ASCT have significantly increased through the use of novel agent-based